Drugs / PIFUSERTIB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04770246 | Mar 2021 → Feb 2023 | PTEN hamartoma tumor syndrome | Taiho Oncology, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT03017521 | Nov 2017 → Dec 2019 | cancer | Yonsei University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-06-04 | Taiho Oncology, Inc. | Results Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020 taihooncology.com ↗
Synergistic antitumor activity of futibatinib, an FGFR1-4 inhibitor, and TAS-117, a selective AKT inhibitor, in FGFR-deregulated cancer models (Abstract 661). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-04 | Taiho Oncology, Inc. | Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020 taihooncology.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIFUSERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297329 ↗ |
| Known as | TAS-117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03017521 ↗ |
| Action | Inhibit | “TAS-117 is a highly potent and selective oral allosteric AKT inhibitor.” NCT03017521 ↗ |
| Modality | Small molecule | — CHEMBL4297329 ↗ |
| Route | Oral | “TAS-117, 16mg, orally, daily” NCT03017521 ↗ |
| Target | AKT1 | “It has high affinity for AKT1, 2, and 3 and shows potent anti-proliferative activity against multiple tumor cell lines in vivo.” NCT03017521 ↗ |